Publications by authors named "Tara Cochrane"

Claim this Profile
M
Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.
Kimberly S Q Wong, Arina Martynchyk, Zoe Krisnadi, Fiona Swain, Ahmad Zargari, Tara Cochrane

J Natl Cancer Inst· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing best practice in the Australian haematology setting for the use of chimeric antigen receptor T-cell therapy for relapsed and refractory lymphoma.
Michael Dickinson, Nicole O'Leary, Nada Hamad, Tara Cochrane, P Joy Ho

Intern Med J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel TERT variant associated with a telomere biology disorder and challenges in variant classification.
Vahid Pazhakh, Lucy C Fox, Nicole Den Elzen, Matthew R Emerson, Scott B Cohen, Tara Cochrane

EJHaem· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma.
Michael P MacManus, John F Seymour, Hennes Tsang, Richard Fisher, Colm Keane, Tara Cochrane

EBioMedicine· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes for high-risk defining events in follicular lymphoma following frontline immunochemotherapy.
Joshua W D Tobin, Venkata A Chikatamarla, Marko Matic, Alison Griffin, Rakin Chowdhury, Tara Cochrane

Blood Neoplasia· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda

Leuk Lymphoma· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study.
Emma Verner, Amanda Johnston, Nalini Pati, Eliza A Hawkes, Hui-Peng Lee, Tara Cochrane

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study.
Allison Barraclough, Shivam Agrawal, Dipti Talaulikar, Geoffrey Chong, Edward Yoo, Tara Cochrane

Haematologica· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study.
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, Pieternella J Lugtenburg, Emmanuel Gyan, Tara Cochrane

Lancet Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance.
Maciej Tatarczuch, Katharine Louise Lewis, Ashray Gunjur, Briony Shaw, Li Mei Poon, Tara Cochrane

EJHaem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
Kate Manos, Leonid Churilov, Andrew Grigg, Pietro Di Ciaccio, Jonathan Wong, Tara Cochrane

Br J Haematol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.
Peter Mollee, John Reynolds, Wojt Janowski, Hang Quach, Philip Campbell, Tara Cochrane

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
Diva Baggio, Eliza Chung, Cameron Wellard, Neil Waters, Tania Cushion, Tara Cochrane

Intern Med J· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Briony Shaw, Eliza Chung, Cameron Wellard, Edward Yoo, Rory Bennett, Tara Cochrane

EJHaem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Ashlea Campbell, Benjamin Teh, Stephen Mulligan, David M Ross, Robert Weinkove, Tara Cochrane

Intern Med J· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphocytic leukaemia Australasian consensus practice statement.
Mary A Anderson, Rory Bennett, Xavier Badoux, Giles Best, Nicole Chia, Tara Cochrane

Intern Med J· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of human immunodeficiency virus-associated Burkitt lymphoma and diffuse large B-cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance.
Kenneth J C Lim, Pietro Di Ciaccio, Mark N Polizzotto, Sam Milliken, Tara Cochrane

Br J Haematol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and Outcomes of Older Patients With Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study.
Zhong Goh, Maya Latimer, Katharine L Lewis, Chan Y Cheah, Pietro Di Ciaccio, Tara Cochrane

Clin Lymphoma Myeloma Leuk· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry.
James Nguyen, Cameron Wellard, Eliza Chung, Chan Y Cheah, Michael Dickinson, Tara Cochrane

Eur J Haematol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study.
Judith Trotman, Peter Presgrave, Duncan P Carradice, Douglas Stuart Lenton, Maher K Gandhi, Tara Cochrane

Hemasphere· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Diva Baggio, Cameron Wellard, Eliza Chung, Dipti Talaulikar, Colm Keane, Tara Cochrane

Leuk Lymphoma· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
Jacinta Perram, Duncan Purtill, Ashish Bajel, Jason Butler, Tracey O'Brien, Tara Cochrane

Intern Med J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial.
Tara Cochrane, Alicia Enrico, David Gomez-Almaguer, Evgueniy Hadjiev, Ewa Lech-Maranda

Leuk Lymphoma· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of a therapeutic platelet transfusion strategy to a prophylactic platelet transfusion strategy in autologous stem cell transplant (ASCT), a single centre experience.
Camille Savoia, Nicholas McKeough, Beth Hickey, Tara Cochrane

Bone Marrow Transplant· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment and management of newly diagnosed classical Hodgkin lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance.
Tara Cochrane, Belinda A Campbell, Shane A Gangatharan, Maya Latimer, Richard Khor

Intern Med J· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis